Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.51M | 1.72M | 1.74M | 1.93M | 1.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.40M | 4.45M | 4.70M | 5.39M | 5.88M |
| Operating Income | -4.40M | -4.45M | -4.70M | -5.39M | -5.88M |
| Income Before Tax | -4.45M | -7.73M | -8.32M | -5.17M | -5.91M |
| Income Tax Expenses | -- | -- | -- | -- | -424.00K |
| Earnings from Continuing Operations | -4.45M | -7.73M | -8.32M | -5.17M | -5.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.45M | -7.73M | -8.32M | -5.17M | -5.49M |
| EBIT | -4.40M | -4.45M | -4.70M | -5.39M | -5.88M |
| EBITDA | -4.37M | -4.42M | -4.66M | -5.35M | -5.84M |
| EPS Basic | -1.59 | -6.81 | -10.72 | -7.53 | -8.03 |
| Normalized Basic EPS | -0.95 | -2.36 | -3.64 | -4.71 | -5.10 |
| EPS Diluted | -1.59 | -6.81 | -10.72 | -7.53 | -8.03 |
| Normalized Diluted EPS | -0.95 | -2.36 | -3.64 | -4.71 | -5.10 |
| Average Basic Shares Outstanding | 2.79M | 1.13M | 775.70K | 685.90K | 683.00K |
| Average Diluted Shares Outstanding | 2.79M | 1.13M | 775.70K | 685.90K | 683.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |